Some chemotherapeutics possess anti-cancer efficacy via inducing cellular senescence, such as Palbociclib, a specific CDK4/6 inhibitor, which was approved in 2015 for clinical treatment of advanced breast cancer [52]. This evidence concerns the gene CDK4 and breast carcinoma.